Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

CGRP Blockade by Galcanezumab Was Not Associated with Reductions in Signs and Symptoms of Knee Osteoarthritis in a Randomized Clinical Trial.

Jin Y, Smith C, Monteith D, Brown R, Camporeale A, McNearney TA, Deeg MA, Raddad E, Xiao N, Peña A, Kivitz AJ, Schnitzer TJ.

Osteoarthritis Cartilage. 2018 Sep 18. pii: S1063-4584(18)31459-6. doi: 10.1016/j.joca.2018.08.019. [Epub ahead of print]

PMID:
30240937
2.

Brain and psychological determinants of placebo pill response in chronic pain patients.

Vachon-Presseau E, Berger SE, Abdullah TB, Huang L, Cecchi GA, Griffith JW, Schnitzer TJ, Apkarian AV.

Nat Commun. 2018 Sep 12;9(1):3397. doi: 10.1038/s41467-018-05859-1.

3.

Effects of Teriparatide and Vibration on Bone Mass and Bone Strength in People with Bone Loss and Spinal Cord Injury: A Randomized, Controlled Trial.

Edwards WB, Simonian N, Haider IT, Anschel AS, Chen D, Gordon KE, Gregory EK, Kim KH, Parachuri R, Troy KL, Schnitzer TJ.

J Bone Miner Res. 2018 Jun 15. doi: 10.1002/jbmr.3525. [Epub ahead of print]

PMID:
29905973
4.

Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study.

McAlindon TE, Schmidt U, Bugarin D, Abrams S, Geib T, DeGryse RE, Kim K, Schnitzer TJ.

Osteoarthritis Cartilage. 2018 Oct;26(10):1291-1299. doi: 10.1016/j.joca.2018.05.001. Epub 2018 May 9.

PMID:
29753118
5.

Inferring distinct mechanisms in the absence of subjective differences: Placebo and centrally acting analgesic underlie unique brain adaptations.

Tétreault P, Baliki MN, Baria AT, Bauer WR, Schnitzer TJ, Apkarian AV.

Hum Brain Mapp. 2018 May;39(5):2210-2223. doi: 10.1002/hbm.23999. Epub 2018 Feb 7.

PMID:
29417694
6.

Hippocampal morphology mediates biased memories of chronic pain.

Berger SE, Vachon-Presseau É, Abdullah TB, Baria AT, Schnitzer TJ, Apkarian AV.

Neuroimage. 2018 Feb 1;166:86-98. doi: 10.1016/j.neuroimage.2017.10.030. Epub 2017 Nov 6.

7.

Tanezumab in the treatment of chronic musculoskeletal conditions.

Jayabalan P, Schnitzer TJ.

Expert Opin Biol Ther. 2017 Feb;17(2):245-254. doi: 10.1080/14712598.2017.1271873. Epub 2016 Dec 25. Review.

PMID:
27936977
8.

A randomized placebo-controlled pilot study of the efficacy and safety of D-cycloserine in people with chronic back pain.

Schnitzer TJ, Torbey S, Herrmann K, Kaushal G, Yeasted R, Vania Apkarian A.

Mol Pain. 2016 Nov 15;12. pii: 1744806916678627. Print 2016.

9.

Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials.

Tétreault P, Mansour A, Vachon-Presseau E, Schnitzer TJ, Apkarian AV, Baliki MN.

PLoS Biol. 2016 Oct 27;14(10):e1002570. doi: 10.1371/journal.pbio.1002570. eCollection 2016 Oct.

10.

Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Aug 30;68(9):981-2. doi: 10.1016/j.jacc.2016.06.008. No abstract available.

11.

Corticolimbic anatomical characteristics predetermine risk for chronic pain.

Vachon-Presseau E, Tétreault P, Petre B, Huang L, Berger SE, Torbey S, Baria AT, Mansour AR, Hashmi JA, Griffith JW, Comasco E, Schnitzer TJ, Baliki MN, Apkarian AV.

Brain. 2016 Jul;139(Pt 7):1958-70. doi: 10.1093/brain/aww100. Epub 2016 May 5.

12.

Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL; COGENT Investigators.

Am J Med. 2016 Sep;129(9):1002-5. doi: 10.1016/j.amjmed.2016.03.042. Epub 2016 Apr 30.

PMID:
27143321
13.

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71. doi: 10.1016/j.jacc.2015.12.068. Epub 2016 Mar 21.

14.

The Emotional Brain as a Predictor and Amplifier of Chronic Pain.

Vachon-Presseau E, Centeno MV, Ren W, Berger SE, Tétreault P, Ghantous M, Baria A, Farmer M, Baliki MN, Schnitzer TJ, Apkarian AV.

J Dent Res. 2016 Jun;95(6):605-12. doi: 10.1177/0022034516638027. Epub 2016 Mar 10. Review.

15.

Zoledronic Acid Treatment After Acute Spinal Cord Injury: Results of a Randomized, Placebo-Controlled Pilot Trial.

Schnitzer TJ, Kim K, Marks J, Yeasted R, Simonian N, Chen D.

PM R. 2016 Sep;8(9):833-43. doi: 10.1016/j.pmrj.2016.01.012. Epub 2016 Jan 30.

PMID:
26828618
16.

Bone Imaging and Fracture Risk after Spinal Cord Injury.

Edwards WB, Schnitzer TJ.

Curr Osteoporos Rep. 2015 Oct;13(5):310-7. doi: 10.1007/s11914-015-0288-6. Review.

PMID:
26277792
17.

The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL.

Aliment Pharmacol Ther. 2015 Aug;42(3):365-74. doi: 10.1111/apt.13260. Epub 2015 May 29.

18.

OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis.

Losina E, Ranstam J, Collins JE, Schnitzer TJ, Katz JN.

Osteoarthritis Cartilage. 2015 May;23(5):677-85. doi: 10.1016/j.joca.2015.03.011. Review.

19.

Reduction in Torsional Stiffness and Strength at the Proximal Tibia as a Function of Time Since Spinal Cord Injury.

Edwards WB, Simonian N, Troy KL, Schnitzer TJ.

J Bone Miner Res. 2015 Aug;30(8):1422-30. doi: 10.1002/jbmr.2474. Epub 2015 May 21.

20.

A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.

Schnitzer TJ, Marks JA.

Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S8-17. doi: 10.1016/j.joca.2014.10.003. Review.

Supplemental Content

Loading ...
Support Center